
CONTENTS

Dedication	v
Preface	vii
Contributors	xi

Part I. Introduction

Chapter 1. Cardiac Safety of Noncardiac Drugs: Historical Recollections	3
<i>Raymond John Lipicky</i>	

Part II. Preclinical and Pharmacogenomic Cardiac Safety Evaluations

Chapter 2. Molecular Physiology of Ion Channels That Control Cardiac Repolarization	13
<i>Jeanne M. Nerbonne and Robert S. Kass</i>	
Chapter 3. Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis	37
<i>Charles Antzelevitch</i>	
Chapter 4. hERG Assay, QT Liability, and Sudden Cardiac Death	67
<i>Arthur M. Brown</i>	
Chapter 5. Pharmacogenomics in Drug Development: When and How to Apply	83
<i>Richard Judson and Arthur J. Moss</i>	

Part III. Clinical Methodologies and Technical Aspects of Assessing Cardiac Safety of Investigational Drugs: Focus on Cardiac Repolarization

Chapter 6. Assessment of Ventricular Repolarization From Body-Surface ECGs in Humans	107
<i>Jean-Philippe Couderc and Wojciech Zareba</i>	
Chapter 7. ECG Acquisition and Signal Processing: 12-Lead ECG Acquisition	131
<i>Justin L. Mortara</i>	
Chapter 8. Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation: Assessment by Different Recording and Measurement Methods	147
<i>Nenad Sarapa</i>	
Chapter 9. Holter Monitoring for QT: The RR Bin Method in Depth	167
<i>Fabio Badilini and Pierre Maison-Blanche</i>	

Part IV. Application of Electrocardiology in Clinical Research

Chapter 10.	Fundamentals of ECG Interpretation in Clinical Research and Cardiac Safety Assessment	189
	<i>Ihor Gussak, Robert Kleiman, and Jeffrey S. Litwin</i>	
Chapter 11.	Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs	205
	<i>Joel Morganroth</i>	
Chapter 12.	Use of ECGs in Support of Cardiac Safety in Phase II and III Clinical Trials	223
	<i>Martin P. Bedigian</i>	
Chapter 13.	Cardiac Arrhythmia Assessment in Phase IV Clinical Studies ...	229
	<i>Gerald A. Faich and Annette Stenhagen</i>	
Chapter 14.	Statistical Analysis Plans for ECG Data: Controlling the Intrinsic and Extrinsic Variability in QT Data	239
	<i>Alan S. Hollister and Timothy H Montague</i>	
Chapter 15.	Interpretation of Clinical ECG Data: Understanding the Risk From Non-Antiarrhythmic Drugs	259
	<i>Rashmi R. Shah</i>	

Part V. Regulatory Considerations

Chapter 16.	The FDA's Digital ECG Initiative and Its Impact on Clinical Trials	301
	<i>Barry D. Brown</i>	
Chapter 17.	Quality Control and Quality Assurance for Core ECG Laboratories	329
	<i>Amy M. Annand-Furlong</i>	
Chapter 18.	ECG Digital Communities and Electronic Reporting of Cardiac Safety Data: New Technologies for Reporting Digital ECG Data in Clinical Research Settings	339
	<i>Scott Grisanti and Robert Brown</i>	
Index		355

Cardiac Safety of Noncardiac Drugs
Practical Guidelines for Clinical Research and Drug
Development

Morganroth, J.; Gussak, I. (Eds.)

2005, XII, 362 p., Hardcover

ISBN: 978-1-58829-515-6

A product of Humana Press